CLYM - NASDAQ

Climb Bio, Inc.

CLYM·NASDAQ

$10.98

-2.0%

HealthcareBiotechnology

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$748.75M

EPS-0.8800

P/E Ratio-12.48

Earnings Date08/11/2026

clym

Total Debt

Last Annual Value

541.00K

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Climb Bio, Inc. Competitors Analysis of Total Debt

CLYM · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Climb Bio, Inc. NASDAQ:CLYM	541.00K	15.7%	N/A	N/A
Inovio Pharmaceuticals, Inc. NASDAQ:INO	9.37M	-32.3%	-22.3%	N/A
Spero Therapeutics, Inc. NASDAQ:SPRO	2.90M	-19.5%	-17.0%	N/A
Turn Therapeutics Inc. NASDAQ:TTRX	80.38K	47.3%	N/A	N/A
Agenus Inc. NASDAQ:AGEN	334.90M	53.2%	41.9%	9.9%
Anixa Biosciences, Inc. NASDAQ:ANIX	204.00K	5.2%	-4.7%	-26.1%
Seres Therapeutics, Inc. NASDAQ:MCRB	82.97M	-25.3%	11.0%	22.7%
Cognition Therapeutics, Inc. NASDAQ:CGTX	638.00K	-19.8%	N/A	N/A
Context Therapeutics Inc. NASDAQ:CNTX	112.06K	N/A	N/A	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	502.67K	-40.2%	-4.8%	N/A
Inhibikase Therapeutics, Inc. NASDAQ:IKT	0.00	N/A	N/A	N/A

Climb Bio, Inc. Fair Value Envelope

CLYM · NASDAQ

Our analysis suggests that CLYM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.9813, this represents a potential HIDDEN relative to our calculated worth for Climb Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $10.9813

Related Guides

Blog Categories

Continue your CLYM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.